A novel potential strategy for treating colon cancer driven by mutations in the KRAS gene has been discovered by Massachusetts General Hospital researchers. In a paper appearing in the Feb. 17 issue of Cell, the team reports that targeting a later step in the pathway leading from KRAS activation to tumor growth may be able to halt the process.
"Not all KRAS-mutant colon cancers are the same," says Daniel Haber, MD, PhD, director of the MGH Cancer Center and co-corresponding author of the Cell report. "About half seem to be very dependent on the KRAS mutation for their survival, whereas the other half can continue growing even when KRAS is suppressed. In the KRAS-dependent tumors, we identified how the mutation augments a pathway well known to be involved in colon cancer and identified a key step toward that pathway which, if suppressed, can induce KRAS-dependent tumor cells to undergo apoptosis or programmed cell death."
Colorectal Cancer Screening
Colorectal screening is done using tests to detect blood in stool, colonoscopy or sigmoidoscopy ordouble contrast barium enema or CT colonography.
Mutations that activate KRAS expression are common in several types of cancer - most frequently colorectal and lung cancers - and are known to indicate treatment resistance. Drugs that directly target KRAS activity have not been successful, and attempts to identify other potential targets have been challenging, since KRAS mutations may function differently in different cancers. The MGH team first set out to determine the percentage of KRAS-mutant tumors that depend on the presence of the mutation for their growth.
Quiz on Colon
Are you suffering from a migraine? It is possible that you have an unhealthy bowel. Strange - but true! This quiz is packed with information on the colon. Participate to learn more!
"Not all genes that are mutated in cancer can be directly targeted by drugs, but this study shows that if you understand the interrelationships between all the signaling pathways in a particular type of tumor, you may uncover a vulnerability that allows you to bypass the 'undruggable target'," says Haber, who is the Kurt J. Isselbacher/Peter D. Schwartz Professor of Oncology at Harvard Medical School and a Howard Hughes Medical Institute Investigator.
"The TAK1 inhibitor we used in this study is not suitable for human administration, but pharmaceutical companies have small-molecule TAK1 inhibitors which have not yet been developed because their potential application was not clear," Haber adds. "Now we need to establish dosage levels where these or related drugs can work against KRAS-dependent colon cancers without being toxic. Those studies, combined with better understanding of the mechanisms underlying this pathway and the consequences of its suppression, will bring us closer to planning for clinical trials."
Source: Eurekalert
Colonoscopy Procedure - Animation
An animation of Colonoscopy that shows the appearance of large intestine or colon by using a thin and flexible viewing tube called the colonoscope.
 Additional Option for Treating Colon CancerA new insight into colon cancer has been obtained by an international research team led by cell biologists at the University of California, Riverside. | Advertisement
|
